All Stories

  1. Pilot randomized controlled trial of the ReFresh online fatigue management programme for people with Parkinson’s disease
  2. The Comprehensive Anxiety and Parkinson’s Scale (CAPS): co-development and initial validation of the long (CAPS-54) and short (CAPS-24) versions
  3. Perceived control as a predictor of medication adherence in people with Parkinson’s: a large-scale cross-sectional study
  4. Psychosocial interventions affecting global perceptions of control in people with Parkinson’s disease: a scoping review
  5. Building from Patient Experiences to Deliver Patient-Focused Healthcare Systems in Collaboration with Patients: A Call to Action
  6. Omega-3, Omega-6, and Polyunsaturated Fat for Cognition: Systematic Review and Meta-analysis of Randomized Trials
  7. Omega-3, omega-6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta-analysis of randomised trials
  8. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
  9. Stimulation of the tibial nerve: a protocol for a multicentred randomised controlled trial for urinary problems associated with Parkinson’s disease—STARTUP
  10. Cognitive profile and determinants of poor cognition in people without dementia in Parkinson’s disease
  11. Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials
  12. The Relationship Between Omega-3, Omega-6 and Total Polyunsaturated Fat and Musculoskeletal Health and Functional Status in Adults: A Systematic Review and Meta-analysis of RCTs
  13. Creation of a database to assess effects of omega-3, omega-6 and total polyunsaturated fats on health: methodology for a set of systematic reviews
  14. Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative
  15. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
  16. Omega-6 fats for the primary and secondary prevention of cardiovascular disease
  17. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
  18. Mixed‐Methods Study Identifying Key Intervention Targets to Improve Participation in Daily Living Activities in Primary Sjögren's Syndrome Patients
  19. Patient-directed self-management of pain (PaDSMaP) compared to treatment as usual following total knee replacement; a randomised controlled trial
  20. Experience of sleep disruption in primary Sjögren’s syndrome: A focus group study
  21. Speech and communication in Parkinson’s disease: a cross-sectional exploratory study in the UK
  22. An investigation into the prevalence of sleep disturbances in primary Sjögren’s syndrome: a systematic review of the literature
  23. Roles of Cognitive Status and Intelligibility in Everyday Communication in People with Parkinson’s Disease: A Systematic Review
  24. What is it like to take antipsychotic medication? A qualitative study of patients with first-episode psychosis
  25. Factors assoiated with non-adherence to oral IBD medication: a systematic review
  26. A Concept Map of What Helps People with HD Live with their Condition
  27. Qualitative evaluation of adherence therapy in Parkinson’s disease: a multidirectional model
  28. A systematic review of non-pharmacological interventions for primary Sjögren’s syndrome
  29. Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease
  30. Systematic Reviews of Occupational Therapy Interventions: Summarizing Research Evidence and Highlighting the Gaps
  31. Developing a service user informed intervention to improve participation and ability to perform daily activities in primary Sjogren's syndrome: a mixed-methods study protocol
  32. Validity of Arabic Version of Beliefs About Medication Questionnaire
  33. Physiotherapy for Parkinson's disease: a comparison of techniques
  34. Adherence therapy improves medication adherence and quality of life in people with Parkinson's disease: a randomised controlled trial
  35. Physiotherapy versus placebo or no intervention in Parkinson's disease
  36. Hypertensive patients' experience with adherence therapy for enhancing medication compliance: a qualitative exploration
  37. Cost-effectiveness of health-related lifestyle advice delivered by peer or lay advisors: synthesis of evidence from a systematic review
  38. Systematic review on factors associated with medication non-adherence in Parkinson's disease
  39. Patient directed self management of pain (PaDSMaP) compared to treatment as usual following total knee replacement: study protocol for a randomized controlled trial
  40. Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease
  41. Comparison of speech and language therapy techniques for speech problems in Parkinson's disease
  42. Physiotherapy versus placebo or no intervention in Parkinson's disease
  43. Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis
  44. Physiotherapy versus placebo or no intervention in Parkinson's disease
  45. Interventions for reducing anxiety in women undergoing colposcopy
  46. The use of carer assisted adherence therapy for people with Parkinson's disease and their carers (CAAT-PARK): study protocol for a randomised controlled trial
  47. Is the use of symphysis-fundal height measurement and ultrasound examination effective in detecting small or large fetuses?
  48. Educating healthcare professionals to act on the physical health needs of people with serious mental illness: a systematic search for evidence
  49. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease
  50. Adherence therapy for medication non-compliant patients with hypertension: a randomised controlled trial
  51. An evidence synthesis of qualitative and quantitative research on component intervention techniques, effectiveness, cost-effectiveness, equity and acceptability of different versions of health-related lifestyle advisor role in improving health.
  52. Survey of speech and language therapy provision for people with Parkinson's disease in the United Kingdom: patients' and carers' perspectives
  53. National survey of speech and language therapy provision for people with Parkinson's disease in the United Kingdom: therapists’ practices
  54. Electronic retrieval of health information by healthcare providers to improve practice and patient care
  55. Occupational therapy for patients with Parkinson's disease
  56. Interventions for reducing anxiety in women undergoing colposcopy
  57. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease
  58. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease
  59. Systematic review of antidepressant therapies in Parkinson's disease☆
  60. Therapies for depression in Parkinson's disease
  61. Amantadine for dyskinesia in Parkinson's disease
  62. Beta-blocker therapy for tremor in Parkinson's disease
  63. Amantadine in Parkinson's disease
  64. Systematic review of paramedical therapies for Parkinson's disease
  65. Recognition of the 60 kilodalton cysteine-rich outer membrane protein OMP2 by CD4+ T cells from humans infected with Chlamydia trachomatis
  66. Physiotherapy versus placebo or no intervention in Parkinson's disease
  67. Occupational therapy for Parkinson's disease
  68. Comparison of speech and language therapy techniques for speech problems in Parkinson's disease
  69. Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease
  70. Non-pharmacological therapies for dysphagia in Parkinson's disease
  71. Ropinirole for levodopa-induced complications in Parkinson's disease
  72. Physiotherapy for Parkinson's disease: a comparison of techniques
  73. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease
  74. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease
  75. Cabergoline for levodopa-induced complications in Parkinson's disease
  76. Identification and characterization of a DR4-restricted T cell epitope within chlamydia heat shock protein 60
  77. ‘Persistent’ forms and persistence of Chlamydia
  78. An alternative pathway of B cell activation: stilbene disulfonates interact with a Cl− binding motif on AEn-related proteins to stimulate mitogenesis